M. J. Carreras

CARDIAC MONITORING IN HER-2 POSITIVE ELDERLY PATIENTS TREATED WITH TRANSTUZUMAB

C., J., J. Cortés, 2014 .

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

F. J. Ramos, E. Wiemer, J. Baselga, 2013, Clinical Cancer Research.

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

J. Tabernero, C. Michie, C. Kahatt, 2013, Cancer Chemotherapy and Pharmacology.

Cancer Therapy : Clinical See related article by Dehm , p . 6064 Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E 7107 in Patients with Advanced Solid Tumors

F. J. Ramos, E. Wiemer, J. Tabernero, 2013 .

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

J. Baselga, J. Tabernero, S. Cosimo, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

4005 Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors?

J. Baselga, S. Cosimo, C. Serrano, 2009 .